Antibody Drug Conjugates Market is expected to reach US$ 29,600.98 million by 2030

Rising Incidences of Cancer Cases Drive Antibody Drug Conjugates Market Growth

According to our new research study on "Antibody Drug Conjugates Market Forecast to 2030 –Global Analysis – by Technology, Application, and Distribution Channel," the market was valued at US$ 7,793.43 million in 2022 and is projected to reach US$ 29,600.98 million by 2030; it is estimated to grow at CAGR of 18.2% from 2022 to 2030.

The rising incidence of cancer is primarily bolstering the demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. The US, China, and India were among the countries with the highest number of cancer cases. GLOBOCAN also estimates that the cancer cases in India would reach ~2.08 million by 2040, representing a rise of 57.5% from 2020. As per the World Health Organization (WHO) data published in February 2022, ~10 million people in the world have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00003494

Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and those who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnoses in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment.

The antibody drug conjugates market is segmented as follows:

The antibody drug conjugates market is segmented based on technology, application, distribution channel, and geography. The antibody drug conjugates market is bifurcated based on technology into cleavable and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022–2030. Cleavable linkers use their structure's chemical trigger or inherent properties to release the cytotoxic payload in the tumor cells. This technology uses pH sensitivity, glutathione sensitivity, and protease sensitivity mechanisms as chemical triggers. The cleavable linker technology is widely used in developing antibody-drug conjugates (ADCs). According to the article “Antibody–drug conjugates: Recent advances in linker chemistry,” published in March 2021, over 80% of the approved ADCs are made using cleavable linker technology. Besponsa (inotuzumab ozogamicin) and Adcetris (brentuximab vedotin) are two notable examples of ADCs synthesized using this technology. These ADCs remain comparatively stable for a long time in blood circulation after releasing hydrophilicity traceless payload. Moreover, cleavable linkers can release the payload intracellularly.

Region Analysis – Antibody Drug Conjugates Market

In terms of geography, the global antibody drug conjugates market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America will hold the largest market share, during 2022–2030. The market in this region is further divided into the US, Canada, and Mexico. The growth of the market in North America is attributed to factors such as increasing research and development for ADCs; rising product approvals; growing awareness about ADCs; and a surging number of mergers, collaborations, and partnerships among market players. In addition, the significantly growing incidence of cancer propels the demand for ADCs for the treatment of patients.

The rise in partnerships among the companies to expand their technologies in different regions is further expected to propel market growth over the forecast period. For instance, in August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated in Japan to develop and commercialize ELAHERE, Immunogen’s ADC therapy. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments for ELAHERE, the payment was based on the FDA’s-accelerated approval. ELAHERE is developed to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones as well as double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing, and it will have an exclusive license to develop and commercialize ELAHERE in Japan.

ADC Therapeutics SA, Pfizer Inc; F. Hoffmann-La Roche Ltd; ImmunoGen, Inc; GSK Plc; Gilead Sciences Inc; AstraZeneca Plc; Astellas Pharma Inc; RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd. are among the leading companies operating in the antibody drug conjugates market.

Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com